Home LiteratureArticle Details
PMID: 429553 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

The Journal of clinical investigation ·Vol. 63 ·No. 2 ·1979-02-00 ·Pages 276-86

Pollack M, Young LS

Abstract

Serum antibodies to exotoxin A and type-specific lipopolysaccharide were measured by passive hemagglutination in 52 patients with Pseudomonas aeruginosa septicemia. Their comparative protective activities were evaluated by relating the titers of each at the onset of bacteremia to subsequent outcome. High acute serum antitoxin and antilipopolysaccharide titers (log2 reciprocal mean titers greater than 5) were associated with survival (76% of 17 with high vs. 46% of 24 with low antitoxin titers, P = 0.05; 85% of 13 with high vs. 48% of 29 with low antilipopolysaccharide titers, P = 0.03). In contrast, neither antibody titer was significantly associated (P less than or equal to 0.05) with patients' age or sex, severity of underlying disease, presence of leukopenia, steroid or immunosuppressive therapy. Despite a correlation between acute titers of the two antibodies (r = 0.33, P = 0.06), they appeared to protect independently and additively. Whereas 75% of 8 patients with high antitoxin titers and only 38% of 16 with low titers survived with low antilipopolysaccharide titers (P = 0.10), 100% (6/6), 73% (8/11), and 38% (6/16) survived, respectively, when both, one, or neither antibody was present in high titer (P = 0.01). Furthermore, the association between high acute serum antitoxin titers and survival was more pronounced in patients with rapidly fatal underlying disease (P = 0.06) and leukopenia (P = 0.12) than in more favorable prognostic and immune categories. These data indicate that serum antibodies to exotoxin A and lipopolysaccharide are found in most patients with P. aeruginosa septicemia and both are protective. Both antibodies may have therapeutic or prophylactic potential, whereas serum antiexotoxin A antibodies may be particularly beneficial in compromised hosts.

MeSH Terms
Adolescent Adult Aged Antibodies/analysis,physiology Antibody Formation Antitoxins/analysis Child Exotoxins/immunology Female Hemagglutination Tests Humans Lipopolysaccharides/immunology Male Middle Aged Pseudomonas Infections/immunology,mortality Sepsis/immunology,mortality
Chemicals
Antibodies Antitoxins Exotoxins Lipopolysaccharides
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Pollack M
Young L S
References (35)
35 references, click to expand
  1. Response of cultured mammalian cells to the exotoxins of Pseudomonas aeruginosa and Corynebacterium diphtheriae: differential cytotoxicity.
    Can J Microbiol. 1977 Feb;23(2):183-9 PMID: 65205
  2. Incidence of exotoxin production by Pseudomonas species.
    Infect Immun. 1977 Apr;16(1):362-6 PMID: 68931
  3. Enzymatically active peptide from the adenosine diphosphate-ribosylating toxin of Pseudomonas aeruginosa.
    Infect Immun. 1977 Jun;16(3):832-41 PMID: 19354
  4. Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa.
    Infect Immun. 1976 Oct;14(4):1077-86 PMID: 11187
  5. Toxicity of Pseudomonas aeruginosa exotoxin A for human macrophages.
    Infect Immun. 1978 Mar;19(3):1092-6 PMID: 417028
  6. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections.
    Infect Immun. 1977 Dec;18(3):596-602 PMID: 412786
  7. Purification of Pseudomonas aeruginosa exotoxin by affinity chromatography.
    Infect Immun. 1978 Jan;19(1):66-70 PMID: 415008
  8. Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2.
    Infect Immun. 1978 Jan;19(1):29-33 PMID: 415004
  9. Structure-activity relationships of an exotoxin of Pseudomonas aeruginosa.
    Infect Immun. 1977 Apr;16(1):353-61 PMID: 406204
  10. Experimental studies on the pathogenesis of infections due to Pseudomonas aeruginosa: direct evidence for toxin production during Pseudomonas infection of burned skin tissues.
    J Infect Dis. 1977 Oct;136(4):555-61 PMID: 409788
  11. Exotoxin production by clinical isolates of pseudomonas aeruginosa.
    Infect Immun. 1977 Mar;15(3):776-80 PMID: 404244
  12. Serum antibody to Pseudomonas aeruginosa exotoxin measured by a passive hemagglutination assay.
    J Clin Microbiol. 1977 Jul;6(1):58-61 PMID: 407250
  13. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.
    Infect Immun. 1976 Oct;14(4):942-7 PMID: 825470
  14. Passive immunity against pseudomonas sepsis during granulocytopenia.
    Infect Immun. 1976 Nov;14(5):1151-5 PMID: 824205
  15. Relationship of colonization with Pseudomonas aeruginosa to development of Pseudomonas bacteremia in cancer patients.
    Antimicrob Agents Chemother (Bethesda). 1970;10:240-4 PMID: 5000256
  16. Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine.
    Nat New Biol. 1971 Feb 17;229(7):209-10 PMID: 5281014
  17. Immunization against Pseudomonas in infection after thermal injury.
    J Infect Dis. 1974 Nov;130 Suppl(0):S152-8 PMID: 4138646
  18. Role of antibody in infections due to Pseudomonas aeruginosa.
    J Infect Dis. 1974 Nov;130 Suppl(0):S111-8 PMID: 4213568
  19. Pseudomonas aeruginosa vaccine in cancer patients.
    Ann Intern Med. 1973 Oct;79(4):518-27 PMID: 4201225
  20. Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification, and characterization of exotoxin A.
    J Infect Dis. 1973 Oct;128(4):514-9 PMID: 4200592
  21. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia.
    Cancer. 1973 Oct;32(4):761-6 PMID: 4201654
  22. Purification and characterization of Pseudomonas aeruginosa exotoxin.
    Infect Immun. 1974 Jan;9(1):113-8 PMID: 4202883
  23. Pseudomonas aeruginosa exotoxin: effect on cell cultures.
    J Infect Dis. 1972 Jun;125(6):631-6 PMID: 4624815
  24. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
    J Infect Dis. 1972 Sep;126(3):277-87 PMID: 4626510
  25. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.
    J Infect Dis. 1972 Sep;126(3):257-76 PMID: 4626509
  26. Type-specific immunity in pseudomonas diseases.
    J Lab Clin Med. 1972 Jan;79(1):47-54 PMID: 4621414
  27. Pseudomonas aeruginosa in a center for cancer research. I. Distribution of intraspecies types from human and environmental sources.
    J Infect Dis. 1972 Feb;125(2):95-101 PMID: 4621413
  28. Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli.
    J Infect Dis. 1976 Jan;133(1):37-45 PMID: 54397
  29. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.
    Proc Natl Acad Sci U S A. 1975 Jun;72(6):2284-8 PMID: 166383
  30. New immunotype schema for Pseudomonas aeruginosa based on protective antigens.
    J Bacteriol. 1969 May;98(2):835-6 PMID: 4977486
  31. Common protective antigen (OEP) of Pseudomonas aeruginosa.
    Jpn J Exp Med. 1975 Oct;45(5):355-9 PMID: 817054
  32. Pseudomonas aeruginosa exotoxin: purification by preparative polyacrylamide gel electrophoresis and the development of a highly specific antitoxin serum.
    Infect Immun. 1976 Jul;14(1):55-61 PMID: 820647
  33. Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia.
    Infect Immun. 1976 Apr;13(4):1139-43 PMID: 819373
  34. Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis.
    Am J Med. 1975 May;58(5):629-36 PMID: 805535
  35. Functional role of antibody against "core" glycolipid of Enterobacteriaceae.
    J Clin Invest. 1975 Oct;56(4):850-61 PMID: 1099119
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1979-02-00
Pages
276-86
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC371950
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com